Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | ADH5 | P11766 | 10/20 | 0.60 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939912 | 1.00 | IDO1 (0.61) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL3118463 | 0.87 | IDO1 (0.61) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL10758443 | 0.86 | CYP4Z1 (0.51) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL7280094 | 0.86 | CYP3A4 (0.67) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| Hydrochloric Acid SCHEMBL5869171 | 0.84 | IDO1 (0.62) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL5868816 | 0.84 | IDO1 (0.54) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL28424338 | 0.83 | ADH5 (0.63) | IDO1ADH5CYP4Z1CYP3A4BAZ2B | |
| SCHEMBL21652707 | 0.83 | ADH5 (0.63) | IDO1ADH5CYP4Z1CYP3A4BAZ2B | |
| SCHEMBL10663235 | 0.83 | IDO1 (0.52) | IDO1ADH5CYP4Z1CYP3A4PDE4A | |
| SCHEMBL17773158 | 0.82 | IDO1 (0.55) | IDO1ADH5CYP4Z1CYP3A4PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4405334-A1 | SORTILIN INHIBITORS | Sortina Pharma AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| CN-117813296-A | CD38 modulators and methods of use thereof | 赛特凯恩蒂克公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| CN-111386118-B | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022076662-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-108200760-B | Benzodiazepine derivatives as RSV inhibitors | 英安塔制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114206856-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | IDO1 4698/4885ADH5 4109/4885CYP4Z1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.